1 25 October 2018
2 EMA/572054/2016 - Track-change version of final version versus public-consultation version

3 Guideline on good pharmacovigilance practices (GVP)

4 Product- or Population-Specific Considerations IV: Paediatric population

Draft finalised by the Agency in collaboration with Member States	6 July 2017
Draft agreed by the EU Network Pharmacovigilance Oversight Group (EU-POG)	25 July2017
Draft adopted by Executive Director	28 July 2017
Release for public consultation	2 August 2017
End of consultation (deadline for comments)	13 October 2017
Revised draft finalised by the Agency in collaboration with Member States	12 July 2018
Revised draft agreed by the EU-POG	10 October 2018
Revised draft adopted by Executive Director as final	25 October 2018
Date for coming into effect	8 November 2018

5

6 This track-change version identifies the majority of changes introduced to the public consultation
7 version of this document as the Agency's response to the comments received from the public
8 consultation. This track-change version is published for transparency purposes and must not be taken
9 or quoted as the final version.

10 * For this reason, the timetable above, and in particular the date of coming into effect, apply only the
11 clean version published as final.

12 For the final version of this GVP chapter and any future updates, please see the GVP webpage of the
13 Agency's website.

Table of contents

Please note that this Tables of Contents does not identify the appropriate page numbers of this track-change version.

P.IV.A. Introduction

The paediatric population is defined in the European Union (EU) as that group~~part~~ of the population ~~aged~~ between birth and 18 years of age. The paediatric population encompasses several subsets. In accordance with current guidelines[1,2], The applied age classification of paediatric patients is:

- preterm newborn neonates: from day of birth through the expected date of delivery plus 27 days;
- ~~pre-~~term and post-term neonates: from day of birth plus~~0 to~~ 27 days;
- infants (or toddlers)~~:~~ from 1 month (28 days) to 23 months;
- children: from 2 years to 11 years; and
- adolescents: from 12 years to less than 18 years[3].

Adverse reactions to medicinal products in the paediatric population need ~~a~~ specific evaluation, as they may substantially differ - in terms of frequency, nature, severity and presentation - from those occurring in the adult population (see P.IV.A.1~~P.IV.A.1~~.). The importance of performing tailored ~~specific research in~~ pharmacovigilance research in~~targeting~~ the paediatric population[4] has been recognised and established. Collection~~, and modalities~~ of pharmacovigilance data ~~collection~~ should take into account that ~~medicines~~ in the paediatric population medicines have ~~a~~ different utilisation patterns~~pattern~~ and are often ~~are~~ used off-label, i.e. intentionally used for a medical purpose not in accordance with the terms of the marketing authorisation.

Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC and Regulation (EC) No 726/2004[5], referred to as the 'Paediatric Regulation', puts~~had put~~ particular emphasis on the collection of safety data in the paediatric population, including data on possible long-term adverse effects.

~~Also,~~ as mandated by this regulation, the European Medicines Agency (the 'Agency') issued the Guideline on the Conduct of Pharmacovigilance for Medicines Used in the Paediatric population (EMEA/CHMP/PhVWP/235910/2005 rev 1), which came into effect in 2007 with the implementation of the Paediatric Regulation.

Since the Paediatric Regulation came into force~~More recently~~, a number of changes in the scientific and regulatory environment have had direct consequences for the conduct of pharmacovigilance in the paediatric population, in particular the following: ~~-~~

~~Since~~ the ~~Paediatric Regulation came into force in 2007, the~~ development of new paediatric medicines - as well as~~, and~~ the 'paediatric'~~paediatric~~ development of medicines that were already marketed -~~,~~ have both increased~~:~~ This is reflected by a growing number of paediatric indications for innovative

[1] ICH-E11(R1) Guideline on Clinical Investigation of Medicinal Products in the Paediatric Population.
[2] Communication from the Commission: Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies (2014/C 338/01).
[3] ~~European Commission; Communication From The Commission Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies (2014/C 338/01): http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/2014_c338_01/2014_c338_01_en.pdf.~~
[4] Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001; 52: 77-83.
[5] ~~Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC and Regulation (EC) No 726/2004: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf.~~

medicines, newly authorised paediatric age-specific formulations, and new paediatric indications for medicines with an existing marketing authorisation[6] for adults[7].

New pharmacovigilance legislation, i.e. Directive 2010/84/EU amending Directive 2001/83/EC (the latter is referenced in this guidance as DIR) and (Regulation (EU) No 1235/2010 amending Regulation (EC) No 726/2004 (the latter is referenced as REG), and Directive 2010/84/EU) came into force in the EU in July 2012, providing for strengthened pharmacovigilance processes for all medicines, irrespective of their authorised indication(s) and population(s). This new legislation introduced changes that are particularly relevant for the paediatric population, in particular the extended definition of adverse reaction - to include harm resulting from overdose, misuse, abuse and medication errors (see GVP Annex I) - and the related broadening of the scope of pharmacovigilance to include evaluation of risks associated with medicines when used outside the terms of the MA including 'off-label use'.

This pharmacovigilance legislation introduced Subsequent to the changes that are relevant for the paediatric population. In particular the extended definition of adverse reaction now acknowledges that adverse reactions may arise from use ofin the scientific and regulatory environment, the product within or outside'Guideline on the terms ofConduct of Pharmacovigilance for Medicines Used by the marketing authorisation or from occupational exposure [DIR Art 101(1)]. Use outside the marketing authorisation includes off-label use, overdose, misuse, abuse and medication errors (see GVP Annex I), which are all important aspects related to the pattern of utilisation of medicines in the paediatric population (see P.IV.A.1.4.).

Consequent to these changes, the previous guideline Paediatric Population' (EMEA/CHMP/PhVWP/235910/2005 —rev .1) needed to be updated, and the revised guidance is now provided in this Product-Specific Considerations Chapter P.IV of the Good Pharmacovigilance Practices (GVP). GVP. This guidance should therefore be read in conjunction with Title IV of the Paediatric Regulation and its Article 34, Regulation (EC) No 726/2004 and Directive 2001/83/EC.

The Taking into account that the general guidance on pharmacovigilance processes in the EU is provided in GVP Modules I to XVI , the creation of this guidance as a GVP Considerations Chapter, aims at integrating paediatric pharmacovigilance withinwith the structures and processes for pharmacovigilance overall.
P.IV therefore applies in conjunction with the GVP Modules I to XVI on pharmacovigilance processes in the EU and does not replace these GVP Modules or introduce regulatory requirements .

In addition to those already covered, the guidance in existing Modules. This Chapter provides guidanceICH E11 Guideline on how to make best useClinical Investigation of the pharmacovigilance tools and processes to address the needs and specific challenges of the paediatric population, and supportsMedicinal Products in the interpretation of how regulatory requirements should be adapted to target this specific population.Paediatric Population[8] applies.

The guidance contained in this Chapter is addressed to marketing authorisation applicants and holders, and to the competent authorities in the Member States and the Agency. Additionally it willIt covers all paediatric age groups and should additionally be of interest both to parents/carers, healthcare

[6] Report from the Commission to the European Parliament and the Council: Better Medicines for Children - From Concept to Reality General Report on experience acquired as a result of the application of Regulation (EC) No 1901/2006 on medicinal products for paediatric use (COM/2013/0443): http://ec.europa.eu/health/files/paediatrics/2013_com443/paediatric_report_com(2013)443_en.pdf.
[7] Report from the Commission to the European Parliament and the Council: Better Medicines for Children - From Concept to Reality - General Report on experience acquired as a result of the application of Regulation (EC) No 1901/2006 on medicinal products for paediatric use (COM/2013/0443).
[8] http://www.ema.europa.eu

professionals, patient/consumer organisations, healthcare professional organisations. ~~and~~ organisations of national healthcare systems in Member States as well as sponsors of clinical studies.~~.~~

This guidance is addressed primarily to cover medicines with a paediatric indication or those with an adult indication and ongoing paediatric development, but also to medicines with an adult indication for which there is evidence of use in the paediatric population.

The paediatric use of vaccines and the safety surveillance of paediatric outcomes after exposure to medicines in utero are outside the scope of P.IV.,~~.~~ as such guidance is covered by~~/will be provided in~~ GVP P.I ~~on vaccines for prophylaxis against infectious diseases~~ and GVP P.III ~~on pregnancy and breastfeeding~~.

P.IV.A.1. Pharmacovigilance aspects specific to the paediatric population

P.IV.A.1.1. Susceptibility to adverse reactions

~~Paediatric subjects differ substantially from adults~~ due to ~~the ongoing neurobehavioural development and physical~~ growth and ~~, including internal organ~~ maturation,~~. Furthermore, within the paediatric population, different maturation milestones are likely to alter~~ the susceptibility of paediatric patients~~sub-population~~ to ~~specific~~ adverse reactions may substantially differ from adults. ~~and the way individuals react to them (e.g. (pre)term neonates to toddlers or pre-/post-pubertal children). This is based on distinct pharmacokinetic and pharmacodynamic characteristics in the respective paediatric age groups.~~

Various factors account~~might influence the susceptibility of the paediatric population to adverse reactions~~ for this difference and ~~a given medicine, compared to the adult population. They~~ include, but are not limited to:~~:~~

- changes in physiology ~~the maturation of organ systems (e.g. skin, airways, kidney, liver, gastro-intestinal, brain and blood-brain-barrier as well as drug transporters)~~ during growth and ~~their~~ development (ontogeny~~), that may lead~~) ~~leading~~ to ~~a~~ different pharmacodynamic and pharmacokinetic parameters in the paediatric subjects compared to adults having an impact on the safety profile of the~~a~~ medicine; ~~as known in adults;~~
- immaturity of some organ systems (e.g. skin, airways, kidneys, liver, gastro-intestinal system, brain and blood-brain-barrier, immune system, bones, drug transporters) that may increase the vulnerability to adverse reactions and their sequelae;
- ~~rapid~~ changes in body mass and composition~~morphology~~ that may lead to a narrowing of~~can reduce~~ the therapeutic window and an~~, leading to~~ increased susceptibility to dose-related adverse reactions;
- ~~•~~ increased sensitivity to~~immaturity of many organ systems that might lead to different vulnerability to adverse reactions in some paediatric subpopulations, such as preterm neonates;~~

- ~~presence of specific~~ pharmacologically active excipients[9] that may lead to an increased~~in the paediatric population may have unintended effects, leading to a~~ risk of adverse reactions.~~;~~

Within the paediatric population itself, the different maturation milestones might alter the susceptibility to specific adverse reactions across the various paediatric sub-populations (e.g. (pre)term neonates to toddlers or pre-/post-pubertal children).

- Moreover, effects~~impact of short and long-term effects~~ on ~~the~~ developing organs and organ ~~-~~ systems ~~-,~~ e.g. on ~~neurological,~~ skeletal growth, ~~and~~ sexual maturation, neurobehavioral development[10] ~~-(such effects~~ may only become obvious, visible or identifiable ~~in the long-term, i.e.~~ with significant~~remarkable~~ delay after exposure or long-term use (i.e. ~~,~~ in adolescence or adulthood).

These considerations highlight the importance of taking into account aspects related to organ maturation, developmental physiology and developmental pharmacology[11] when planning~~performing~~ pharmacovigilance activities for the paediatric population. Considerations for ~~and imply that the value of~~ long-term follow-up should carefully take these factors into account~~be considered systematically~~.

P.IV.A.1.2. Limited numbers of subjects in paediatric clinical trials

Clinical trials conducted in adults have ~~The well-~~known limitations in generating ~~of clinical trials in the generation of data on the~~ safety data. Trials often are limited in size and in duration, might exclude high-risk populations and have limited statistical power to detect rare, but potentially serious, adverse reaction that will only be detected in the real-world setting. These limitations ~~profile of a medicine~~ are even more relevant~~pertinent~~ for ~~the~~ paediatric clinical trials.

~~population.~~ Due to the ~~challenges of conducting clinical trials in the paediatric population, the amount of dedicated information on the safety of medicines in neonates, children and adolescents at the time of marketing authorisation can be very limited.~~

~~The~~ small numbers of ~~paediatric~~ patients that is generally possible to enrol, ~~in~~ paediatric clinical trials often have a sample size that is~~does~~ not statically~~allow for a statistically~~-powered ~~design~~ for demonstration of efficacy and cannot ~~. This has also an impact on the potential of clinical trials to~~ gather a sufficient number of participants~~numbers~~ for collecting precise~~generating dedicated~~ information on the incidence of adverse reactions, particularly in some paediatric age sub-groups. ~~in the same fashion of adult clinical trials.~~

~~Due to low numbers of patients enrolled in paediatric clinical trials and/or to the long latency between exposure to the medicinal product and the onset of the reaction,~~ adverse reactions that are rarer than 'common', i.e. occur~~occurring~~ at a frequency of less than 1/100[12], ~~common~~ may not be detectable in clinical trials. Also, the duration of such trials is usually limited, and adverse reactions that have a long latency between exposure and onset might not be adequately captured~~during the pre-authorisation phase~~.

[9] Guideline on pharmaceutical development of medicines for paediatric use (EMA/CHMP/QWP/805880/2012 Rev. 2), https://www.ema.europa.eu/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf.~~2):~~
~~http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf.~~

[10] Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews. 2012 Issue 11. Art. No.: CD004851.

[11] Tayman C, ~~.,~~ Rayyan M, ~~.,~~ Allegaert K. Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther. 2011; 16(3): 170-184.

[12] European Commission. A guideline on summary of product characteristics (SmPC). Rev 2; 2009 (in Volume 2C of the Rules Governing Medicinal Products in the European Union).

Overall, this means that~~Furthermore,~~ the ~~size of the paediatric~~ safety data collected for neonates, infants, children and adolescents~~database available~~ for a given medicine~~,~~ in comparison to what is generally available for adults at the time of granting the marketing authorisation, can be particularly limited. ~~, can be scarce or a paediatric safety database may not even be available.~~

P.IV.A.1.3. Medication errors

A medication error is an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the patient (see GVP Annex I). Medication errors can occur at the time of prescribing, storing, dispensing, preparing as well as administering a medicine~~dispensing, storing, preparing and administering a medicine. In comparison to the adult population, the impact of medication errors on the paediatric population can be much more serious. Paediatric patients are up to three times more likely to experience potential adverse reactions due to medication errors than adults[13,14]. Adverse reactions deriving from medication errors may be preventable and it is possible to enact a series of error reduction strategies[15]~~.

Historically, there has been limited~~a lack of~~ development of medicines for paediatric patients, leading to the absence of specific ~~and of~~ paediatric dosing guidance in the product information, and scarcity of age-appropriate pharmaceutical forms or presentations. Due to the limited availability of medicines with an authorised paediatric indication and/or with an age-appropriate pharmaceutical form, paediatric patients may be treated at dosages that are inferred from adult patients, solely based on weight considerations, or with inappropriate pharmaceutical forms (e.g. tablets instead of syrups or drops).

Such widespread practice of off-label use (see P.IV.A.1.4.) was, and still is, associated with a risk of ~~leading to~~ medication errors. Since these medication errors might lead to the administration of inappropriate doses (such as overdose or sub-therapeutic dose), paediatric patients are exposed to a higher risk of developing adverse reactions than adults[16,17].

Furthermore, the consequences of such medication errors in can also be much more serious particularly in the most vulnerable paediatric age sub-groups such as neonates.

It is expected that increased availability of new products with specific paediatric indications and age-appropriate form and presentations (see P.IV.A.1.) will reduce adverse reactions deriving from medication errors in the future.

The Pharmacovigilance Risk Assessment Committee (PRAC) Good Practice Guide on Risk Minimisation and Prevention of Medication Errors[18] provides guidance on the systematic assessment and prevention of medication errors throughout the product life-cycle and contains ~~, with~~ additional considerations applicable to paediatric patients. These include calculation tables in educational material, appropriate dispensing devices and presentations and recommendations for enhanced communication between healthcare professionals, patients and their parents/carers. Advice on appropriate prescribing, storing, dispensing, preparing and administration of medicines, as well as monitoring of patients is also

~~[13] Kaufmann J. et al. Medication Errors in Pediatric Emergencies: a systematic analysis. Deutsches Ärzteblatt International. 2012;109(38):609-616. doi:10.3238/arztebl.2012.0609.~~
~~[14] Kaushal R. et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120.~~
~~[15] Marlene R Miller, Karen A Robinson, Lisa H Lubomski, Michael L Rinke, Peter J Pronovost. Medication errors in paediatric care: a systematic review of epidemiology and an evaluation of evidence supporting reduction strategy recommendations Qual Saf Health Care 2007;16:116–126. doi: 10.1136/qshc.2006.019950~~
[16] Kaufmann J, Laschat M, Wappler F. Medication errors in pediatric emergencies: a systematic analysis. Deutsches Ärzteblatt International. 2012; 109(38): 609-616.
[17] Kaushal R, Bates DW, Landrigan C. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001; 285(16): 2114-2120.
[18] www.ema.europa.eu. ~~www.ema.europa.eu~~

provided. Such strategies and measures for risk minimisation and prevention of medication errors should be considered when developing paediatric medicines or risk management plans~~in paediatric patients~~.

P.IV.A.1.4. Off-label use

Off-label use indicates~~relates to~~ situations where a medicinal product is intentionally used for a medical purpose not in accordance with the terms and conditions of the marketing authorisation. Relevant cases are where the use of a medicine is indicated solely for adults, but is nonetheless used in paediatric subjects (possibly with a different dosage, different route of administration and/or to treat a specific paediatric condition) (see GVP Annex I), or when a paediatric indication exists that is limited to some paediatric age sub-groups, but the product is also used in other age sub-groups (e.g. a medicine is indicated only in adolescents but is used also in children~~of the marketing authorisation, and this includes use in non-authorised paediatric age categories (see GVP Annex I~~).

Off-label use of medicines ~~that did not have an authorised indication~~ in paediatric patients has~~had~~ been a common~~widespread~~ practice, due to the fact that paediatric-specific medicinal products were not available, but necessary therapy could not be withheld. ~~from the paediatric population. This overall exposes paediatric patients to a potentially increased risk to develop adverse reactions, due to the lack of knowledge on the medicine's safety profile in this population.~~

With the developments described in P.IV.A., ~~P.IV.A.,~~ the situation nowadays has improved, but there are still a number of medical~~paediatric~~ conditions where the need for~~of~~ specific paediatric medicines is not met and off-label use continues~~.~~
~~Furthermore, due to the limited availability of medicines with an authorised paediatric indication or an age-appropriate formulation, paediatric patients are likely to be treated with inappropriate formulations or dosages that are inferred from adult patients solely based on weight. This can expose patients to over- or underdosing which, in turn, may lead to an increased risk of adverse reactions and a lack of therapeutic effect. This risk is further increased in more vulnerable paediatric groups such as neonates~~.

Such off-label use, as discussed above, might expose paediatric patients to an increased risk of medication errors and of adverse reactions. Therefore, it is relevant that important risks arising from off-label use in paediatric patients are addressed appropriately (see P.IV.B.1.).

~~In addition, even medicines that have an authorised paediatric indication can be used off-label when they are prescribed in non-authorised paediatric age groups.~~

P.IV.A.1.5. Clinical presentation of adverse reactions

Signs and symptoms of adverse reactions and their clinical course may be different in paediatric patients compared to adults. This is also true among the various paediatric age sub-groups. Non-specific symptoms, such as vomiting and diarrhoea as well as sleepiness or variation in the intensity and pattern of crying, can be the only manifestations of some adverse reaction observed in neonates, infants and toddlers. Moreover,~~The clinical presentation of adverse reactions in neonates and children may be different from adults. Most~~ symptoms that are dependent on patient communication ability (e.g. nausea, pain, mood alterations)~~hallucinations) were under-represented~~ in younger or mentally disabled children[19] might be under- or misreported.

[19] Andrews EB, Moore N, eds. Mann's Pharmacovigilance. 3rd ed. Wiley-Blackwell: 2014.~~ Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children: a systematic review. PLOS ONE. 2012;7:e24061,19.~~

This means that the clinical presentation of adverse reactions can be ~~in a large single centre study. In addition, some of the most common adverse drug reaction types observed in inpatients/outpatients infants and toddlers, such as vomiting and diarrhoea as well as dizziness or crying are~~ non-specific and be misinterpreted as the manifestation of a pre-existing condition. As such ~~might be ascribed to an underlying illness in the first place. This may mean that~~ these reactions will be ~~events are~~ less likely to be suspected and reported~~assessed as adverse reactions~~.

Aspects relating to the modalities of presentation of adverse reactions in the paediatric population (see P.IV.B.5.) need to be taken into account when choosing the most appropriate search terms for performing signal detection (e.g. Lowest Level Terms and Preferred Terms when performing Standardised MedDRA Queries (SMQs)). This is also important when planning pharmacovigilance activities that might involve an active role of the paediatrician and of parents/carers, as they should be enabled to interpret particular signs and symptoms (e.g. crying and pain).

P.IV.B. Structures and processes

P.IV.B.1. Risk management plan (RMP)

The current requirements for risk management plans~~plan~~ (RMP) in GVP Module V and the~~(see also EMA~~ Guidance on the Format of the Risk Management Plan (RMP) in the EU ~~–~~) in integrated format[20] includes~~GVP Module V include~~ considerations for ~~applicable to~~ the paediatric population.

~~In general, the knowledge gained from the adult population – when available - should inform best use of data collection methods and risk minimisation tools when approaching risk management for paediatric subjects[21]. The limitation of~~ methods used to minimise risk of adverse reactions in the adult population ~~need to be appraised and some approaches~~ should be evaluated and adapted~~subject to adaptation~~ to ~~target~~ paediatric patients, taking into account the aspects specific to the paediatric population (P.IV.A.1.) ~~more effectively.~~

In terms of pre-clinical evidence, results of juvenile animal toxicology studies can have a predictive value in terms of effects in the paediatric population and can support prioritising pharmacovigilance research questions (e.g. accumulation of active substance in some organs of the animals tested, impairment in some behavioural tests).

Regarding existing clinical data, the knowledge gained from studies in the adult population should support in the identification of important potential risks, in the characterisation of the safety profile as well as the description of tools to reduce the risk related to the use of the product[22] in the paediatric population.

Sometimes ~~However, there might be~~ no previous clinical or real-world data from adults are existing: this might happen~~experience in adults to build upon~~ when a medicine is authorised exclusively for paediatric patients or when it is authorised for adult~~for adults~~ and paediatric patients at the same time~~, or it is licensed exclusively for paediatric patients, since use in real world has not yet taken place~~.

[20] www.ema.europa.eu.

~~[21] Hartford CG1, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. 2006;29(8):657-673.~~

[22] Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. 2006; 29(8): 657-673.

Conversely, a ~~For medicinal products with a~~ paediatric indication might be added after considerable post-marketing experience has been gained in adults. Therefore, the amount of available evidence can vary greatly.

~~, a number of safety topics are of particular interest for the risk identification discussion in the RMP and they should be discussed if they lead to possible specific risks.~~ Particularly important aspects to be considered for paediatric patients for the purpose of risk identification and characterisation include~~subjects are~~:

- age-related shifts in the interaction of the medicinal product with~~and~~ its target organs or tissues; ~~(including taking into account development and maturation of tissues like in the gastro-intestinal tract);~~
- ontogeny of the absorption, distribution, metabolism and excretion (ADME)~~,) of the medicine,~~ including disposition in intra-individual structures (such as the blood-brain barrier), of an active substance;
- ~~age-related shifts in metabolic pathways related to ontogeny of ADME;~~
- potential adverse reactions~~effects~~ due to different exposure to (different) metabolites as opposed to the adult age~~;~~.
- long-term effect on developing reproductive and neurodevelopmental systems;
- effects on bone and cartilage during active growth phase;
- impact on maturation of the immune system in the pathogenesis of known adverse reactions and effect of transition from passive maternal immunity to maturing immune systems in infants.

Evaluation of these aspects can help in assessing whether a risk of adverse reactions for a given medicine might differ from the adult population and whether its pharmacological properties suggest~~justify~~ any possibility of developmental risk.
Similarly, when it is anticipated that a subgroup of the paediatric population is likely not to be different from the adult population (e.g. post-pubertal children, children above a certain age and/or weight), this should be supported by evidence and discussed at the time of the initial marketing authorisation application.

~~Results of juvenile animal toxicology studies, based on the current understanding of their predictive value in terms of subsequent effects in the paediatric population[23], can also provide a useful support in prioritising pharmacovigilance research questions.~~

If a specific paediatric risk is highlighted and is included as a safety concern in the ~~safety specification of the~~ RMP - in line with the guidance provided in GVP Module V ~~-~~, consideration should be given as to whether a paediatric post-authorisation safety study (PASS) (see P.IV.B.4.)~~P.IV.B.4.)~~ would be ~~an~~ appropriate for~~tool to~~ further characterising~~characterise~~ this risk. ~~The conduct of a PASS in the paediatric population, or to include paediatric subjects in the population studied in a PASS, may be of particular value when:~~

~~[25] ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (CPMP/ICH/286/95): http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002941.pdf.~~
~~[26] International Conference on Harmonisation ICH Topic S 5 (R2). Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility. (CPMP/ICH/386/95): http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002809.pdf.~~

- ~~the medicine is authorised for both the adult and paediatric population at the same time, to evaluate risks when safety information is more limited in the paediatric population or in one of its subsets;~~
- ~~it is anticipated that effects on development can only manifest years after medicine exposure;~~
- ~~the paediatric clinical development and the application for a paediatric indication[24], relies heavily on extrapolation of adult or paediatric sub-group efficacy data.~~

P.IV.B.2. Management and reporting of adverse reactions

Spontaneous reporting is an indispensable pharmacovigilance tool, which ~~of adverse reactions collected during the post-authorisation phase~~ may even be the only ~~available primary~~ source of information on adverse reactions occurring in the paediatric population in the post-authorisation phase for some medicines~~and therefore remains, together with signal detection (see P.IV.B.2.) the most important pharmacovigilance tool so far~~.

Since the use of medicinal products in the paediatric population might occur off-label, data from spontaneous reports can be instrumental in discovering new, specific or more serious adverse reactions in the paediatric population in comparison to that found in the authorised population.

The legal requirements and general guidance for the management and reporting of adverse reactions to be followed, including adverse reactions resulting from off-label use, are described in GVP Module VI.

Reporting systems in place should ensure that the relevant data on paediatric cases (see P.IV.B.2.1. and P.IV.B.2.2.) are fully obtained.

Staff performing pharmacovigilance activities~~Currently, the reporting requirements of individual case safety reports (ICSRs) for the paediatric population, including those related to the off-label use, are not different from adults.~~

~~The generation of knowledge of adverse reactions reported in the framework of off-label use in the paediatric population is extremely important and could potentially serve as a substantial part of adverse reactions collected in the paediatric population.~~

~~Reporting systems should take this aspect into account to support generation of hypothesis on whether off-label use can be an independent risk factor in developing adverse reactions.~~

~~GVP Module VI includes guidance on how to collect and assess information on off-label use and potential or actual harm and enables the collection of important information on the safety of medicines in the paediatric population, where medicines are often used off-label.~~

~~However, those managing ICSRs and assessing risks of medicine use in paediatric patients~~ should have appropriate skills and training to address the aspects specific to the paediatric~~this~~ population (see P.IV.A.1~~P.IV.A.1.~~), including for identifying~~to identify~~ and obtaining~~obtain~~ specific information needed for adequate signal identification, ~~case~~ review of individual case safety reports (ICSRs) and risk assessment.

[24] ~~EMA/199678/2016 Reflection Paper on Extrapolation of Efficacy and Safety in Paediatric Medicine Development. http://www.ema.europa.eu~~

Where off-label use is involved, complete ICSRs can support the generation of hypothesis on whether off-label use is more likely to be associated with an increased reporting of adverse reactions (e.g. an association of off-label use leading to over- or under-dosing and formulation related issues). Therefore completeness of ICSRs is important.

P.IV.B.2.1. Age information

Information on the patient's age in ICSRs should be recorded as accurately as possible (i.e.~~e.g. gestational age for pre-term neonates, in~~ completed days for neonates, days or months for infants and toddlers, and completed years or months for children and adolescents).

Useful data retrieval and analysis can only be performed if age information is reported~~ and available~~, and this information should be available in the structured data fields of the ICSR (rather than only in the narrative).

As far as possible, the ICSRs should indicate either:

- the age at time of onset of reaction or the date of birth, and for neonates, pre-term neonates and infants in addition the gestational age; or
- affiliation to one of the ~~five~~ paediatric age subsets~~groups (see P.IV.A.)~~ if it is not possible to obtain the exact age or date of birth or if personal data protection legislation do not permit ~~prevent~~ this in order to prevent identifying~~identify~~ the patient, in particular when the medical condition is rare.

If no age-related information is provided by the initial reporter, the ~~competent authority and the~~ marketing authorisation holder or the competent authority should request,~~take follow-up action~~ as appropriate, follow-up information on~~in order to obtain~~ age~~-related data~~.

Additionally, information on major developmental parameters like prematurity, pubertal development stage or cognitive and motor developmental milestones should be collected and reported when relevant to~~, as applicable. In this context, information on maternal and paternal exposure during conception and on pregnancy may also be of relevance since they can constitute independent risk factors for~~ the suspected~~development of~~ adverse reaction, because maturation can highly vary in children and can be clinically more important than age. ~~reactions.~~

Particularly in younger subjects, information on maternal~~For neonates~~ and paternal exposure to medicines during conception or pregnancy as well as exposure~~infants, the gestational age~~ of the neonate/infant through breastfeeding may also be of relevance since such exposure can lead to adverse reactions in the off-spring.

Additionally, information on ~~child at~~ birth history as well as major developmental parameters should be collected when possible and where relevant.~~also be recorded.~~ Maturation at that early time of life is rapidly evolving and cellular metabolism, receptor expression, receptor activity, enzymatic activity interrelate strongly with growth. Therefore, precise information on this can reveal factors leading to a different pattern in susceptibility to an adverse reaction in term or pre-term neonates.

P.IV.B.2.2. Other ~~specifically relevant~~ information relevant to the paediatric population

Paediatric ICSRs should also include ~~high quality~~ data as complete as possible on:

- ~~~~indication or intention of use, ;~~
- ~~formulation and dosage form;~~

- ~~dose (including individual and total daily dose), duration and circumstances of exposure,~~ including information needed to establish whether the adverse reaction has developed in association with a ~~framework of~~ medication error~~errors~~ or off-label use;
- pharmaceutical form and strength of the medicinal product;
- dosage prescribed and/or administered (including single, daily and/or total dose as well as dosing schedule), duration and circumstances of exposure, method used to determine the dosage and treatment compliance;
- weight and height/length at the time of the reaction, as these can vary considerably across an age group and influence the susceptibility to an adverse reaction.

The ICSRs should be as complete as possible regarding the concerned data fields and be subject to follow-up requests if these are~~were~~ missing, as appropriate. It is important to capture this information, as The robustness of the output and conclusion of the scientific~~signal validation and~~ assessment will be~~(see P.IV.B.2.) is~~ directly related to the quality of the information included in the ICSRs~~ICSR~~.

~~In the case of products of low usage in the paediatric population, signal detection systems could prove less effective. A different, more proactive approach may be needed to conduct pharmacovigilance for low usage products, for example using real-life data from patients' records or disease databases and active surveillance systems. Clinical specialist networks and paediatric clinical trial networks may also be a useful resource to be consulted in this context such as those being part of the European network of paediatric research at the European Medicines Agency (Enpr-EMA).~~

P.IV.B.3. Periodic safety update report (PSUR)~~reports~~

The requirements for periodic safety update reports (PSUR) as described in ~~included~~ GVP Module VII should be followed.

When a paediatric indication has been granted~~authorised~~, ongoing monitoring of the risk-benefit balance specifically for this indication throughout the product life-cycle ~~via the PSUR~~ should be performed (unless exempted from PSUR submission with a justification) via the ~~, as~~ PSURs, as they are an important tool to collect and cumulatively analyse information on paediatric use. PSURs should explicitly address any new safety issue identified in the paediatric population overall (and when feasible paediatric age sub-groups) and by indication. Discussing and assessing the use of medicines and their effects in real life is the purpose of the PSUR, and this applies not only when a medicine has a paediatric indication but also when information of the safety of a medicinal product used in paediatric patients has been derived from the evaluation of other data related to:~~as well as in age groups and by indication.~~

- off-label use, including the use of not 'age-appropriate' formulations or use in paediatric sub-groups for which the product is not authorised; or

an identified signal of a ~~Assessing and discussing the use of medicines and their effects in real life is the purpose of the PSUR, which should include the paediatric population specifically (unless exempted from PSUR submission). This should be done not only when a medicine has a paediatric indication but also when:~~

- ~~there is evidence of substantial paediatric use in the absence of a paediatric indication (or on the use of not age appropriate formulation) and there are critical gaps in knowledge for specific safety issues; or~~

- paediatric adverse reaction~~reactions have been previously reported~~.

In both these situations~~Furthermore~~, information on ~~:~~

- the number of paediatric patients exposed during the PSUR reporting interval, the exposure of patients by age sub-group~~period~~ and the method of exposure calculation should be included in the PSUR.~~; and~~

It is acknowledged that in some cases it is difficult to obtain and validate paediatric exposure data. Nevertheless, estimations based on available sources (see GVP Module VII), or a justification if it is not possible to draw accurate estimations, should be provided. Safety related findings arising from ongoing or completed paediatric clinical trials should also be discussed.

- ~~significant findings arising from paediatric clinical trials;~~

~~should be included in the PSUR.~~

The addition of a paediatric indication to an existing marketing authorisation implies~~means~~ that the population using the medicine will be widened. It is considered ~~In some cases it would be~~ beneficial to gather further insight on the benefit-risk balance in this~~such~~ widened population~~use~~ and in certain cases this may lead to a requirement for a change towards a higher frequency of PSUR submissions, which can be requested by a competent authority, on a case-by-case basis, or proposed by the marketing authorisation holder for agreement~~has to be considered and agreed~~ at the time of the granting of an~~the~~ extension of the ~~paediatric~~ indication.

P.IV.B.4. Post-authorisation safety studies (PASS)

~~The requirements~~ for the paediatric population,~~design and conduct of~~ post-authorisation safety studies (PASS) ~~in GVP Module VIII should be followed.~~

~~For the paediatric population, PASS~~ are important additions~~complements~~ to the research already conducted as part of pre-authorisation development[25], as they can fill in~~potential~~ gaps in the knowledge of the safety profile of the medicine and complement other activities such as signal detection performed on spontaneously reported adverse reactions. The conduct of a PASS in the paediatric population, or inclusion of paediatric patients in a PASS study population, may be of particular value when:~~spontaneous reports. Some types of PASS such as drug utilisation studies may be useful in describing how the medicine is used in the paediatric populations in real-life clinical practice, e.g. how frequently and which paediatric groups are treated. Furthermore, PASSs are important to understand the effectiveness of risk minimisation measures.~~

- it is anticipated that effects on development can only manifest years after medicine exposure;

[25] Andrews EB, Moore N, eds. Mann's Pharmacovigilance. 3rd ed. Wiley-Blackwell~~:~~ 2014.

- the paediatric clinical development and the paediatric indication[26] relies heavily on extrapolation of adult or paediatric sub-group efficacy data (a paediatric PASS could be considered to investigate long-term safety in children which would have been identified as missing information in the RMP as applicable (see P.IV.B.1.);
- data on long-term safety are needed because of chronic use, particularly for medicines with innovative mechanism of action and/or when chronic use in younger children is expected (i.e. neonates, infants, children below 6 years);
- there is a high likelihood of off-label use in paediatric patients and a safety issue has been suspected as derived from such use (this risk should have been included as an important potential risk in the RMP (see P.IV.B.1.)).

The requirements for the design and conduct of post-authorisation safety studies (PASS) as described in GVP Module VIII should be followed. The design and conduct of PASS in the paediatric population should take into account the specific characteristics of the paediatric sub-populations (see P.IV.A.1.) which may result in effect modification due to a number factors (e.g. relating to child physical maturation and development).~~(sub-)population under investigation (P.IV.A.1.), that may lead in confounding due to factors relating to child development, imprecise diagnostic coding and medical record limitations, as well as lack of consensus about best research standard for paediatrics in some areas. Challenges arising from specific ethical and feasibility aspects could compromise PASSs conduction. Therefore such aspects should also be addressed in a PASS protocol demonstrating that they will be appropriately managed.~~

There might be a lack of consensus about the best research methodological tools in relation to some aspects characteristic to the paediatric population (e.g. misclassification of exposure data, need to choose appropriate risk window, imprecise diagnostic coding and medical record limitations) and this needs to be taken into account in order to choose the most appropriate approach. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology[27] provides useful recommendations to address paediatric-related aspects of observational studies and should be taken into account.

Ethical and feasibility aspects may also compromise the implementation and conduct of PASS. Therefore, when developing of a PASS protocol, a PASS feasibility report should also be considered in order to demonstrate that these aspects will be appropriately managed (e.g. providing estimated recruitment figures based on evidence or a remedial strategy in the case that the target patient number is not reached in time) as this can support the smooth implementation of the study.

Disease or treatment registries and national healthcare databases can be used for the conduct of non-interventional PASS[28]. However, since~~, but because of~~ the inclusion of paediatric patients in these types of data sources can be limited, multi-database approaches should be considered to achieve appropriate study sizes.

Planning a PASS early.~~In many cases high level planning for such studies should already be considered~~ at the same time when~~of submission of a Paediatric Investigation Plan (PIP, see 0), to promote continuity between~~ the clinical development is defined, can enable a synergist approach supporting a more fruitful strategy for the integration of ~~safety~~ data to be produced prior to ~~generation in the pre- and post-~~marketing authorisation with~~phase. An early planned study would facilitate understanding on~~

[26] Reflection Paper on Extrapolation of Efficacy and Safety in Paediatric Medicine Development (EMA/199678/2016), www.ema.europa.eu.
[27] www.encepp.eu/standards_and_guidances.
[28] de Bie, S et al. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. Br J Clin Pharmacol. 80: 304-314.

possible types of data that willcan be collectedgathered after marketing authorisation. An early planning and can also help in a better definition of thesupport in defining main characteristics and requirements for future paediatric registries to be put in place. They couldthat can be set-up more promptly, enabling researchers to address safety-relatedresearch questions arisen in the pre-authorisation phase once a product is authorised more promptlymarketing phase.

The template for PASS protocols (see GVP Module VIII, Guidance for the Format and Content of the Protocol of Non-Interventional Post-Authorisation Safety Studies[29]) should be completed, taking into account specifics for paediatrics as follows:

- template heading 8 "Research question and objectives": this may relate to alterations in somatic growth, puberty, cognitive or physical development;
- template heading 9.4 "Data sources": if information from other family members or from external data sources, such as census data, is needed, the linkages to external data sources and the sources should be described (e.g. exposures and events in neonates are often included in the mother's clinical record rather than in a separate record for the child);
- template heading 9.7 "Data analysis": the statistical methods may need to be adapted to account for paediatric-specific aspects (e.g. the correlation between repeated measurements such as weight and height)in the same child which may vary in short periods of time; changes in recommended dosing as the child grows).

P.IV.B.5. Signal management

A signal is the information arising from one or multiple sources, including observations and experiments, suggesting a new potentially causal association, or a new aspect of a known association, between an intervention and an event, or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action [Commission Implementing Regulation (EU) No 520/2012, Art 19(1) (hereafter referred to as IR 520/2012)].

For the purpose of monitoring data in the EudraVigilance database, only signals related to an adverse reaction shall be considered [IR 520/2012 Art 19(1)] (see GVP Annex I). Guidance for signal management as provided in GVP Module IX should be followed.

Signal management activities focussing on the paediatric population should take into account the expected differences in this age group compared to adults, as previously discussed, due to the different utilisation, prescription, adverse reaction susceptibility and clinical presentation (see P.IV.A.1.).

Further, it has been shown that the types of medicines and the suspected adverse reactions commonly reported in spontaneous reports, differ substantially between paediatric patients and adults, not only in terms of reaction types and medicinal products involved, but also in the fact that they are more concentrated around limited sets of reaction types and medicinal product type, such as vaccines[30]. Hence, performing paediatric statistical signal detection may benefit from tailored approaches as well

[29] www.ema.europa.eu

[30] Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Paediatr Drugs. 2014;16(4):309-319.

~~as specific tools to study a heterogeneous population, weighing whether age group may be a confounder or an effect modifier.~~

~~Such tailored approaches aim firstly at addressing whether an adverse reaction is new or more severe than previously known, in one or all paediatric age groups.~~

~~Qualitative differences in usage of medicines and reporting of adverse reactions have suggested that paediatric ICSRs should be analysed separately from ICSRs about adult patients in the systems like the electronic Reaction Monitoring Reports (eRMRs) produced by EudraVigilance[31].~~

Another approach to enhance signal detection in the paediatric population may be focussing on~~targeting~~ reported medical events that are particularly relevant in this population, i.e. adverse reactions that can be~~are~~ more frequently associated with a fatal or more serious outcome when they occur in paediatric patients as compared to adults.

It has been shown that the more commonly reported classes of medicines and suspected adverse reactions described in spontaneously reported ICSRs, differ substantially between paediatric and adult patients; not only the reaction types and medicinal products involved are different, but they are also more concentrated around limited sets of reaction types and medicinal product types, such as e.g. vaccines[32]. Qualitative differences observed in the usage of medicines and in the reporting of adverse reactions have suggested that, when existing, paediatric ICSRs should be analysed independently from ICSRs in adult patients by competent authorities and marketing authorisation holders.

When paediatric signal detection is performed, tailored statistical approaches as well as specific tools to study a heterogeneous population should be considered aiming at identifying whether in one or all paediatric age sub-groups an adverse reaction is new, more severe or more frequent than previously known or if there are any differences in the reversibility of the reaction. Together with appropriate clinical considerations, they should also aim at investigating confounding or effect modification by specific age sub-groups.

When using statistical algorithms in signal detection~~As for the general population, statistics of disproportionate reporting (see GVP Module IX Addendum I) should be calculated using only ICSRs about paediatric patients to increase the ability to detect paediatric signals of disproportionate reporting (SDR) from spontaneous databases. Sub-group analysis by age and comparison of the disproportionality statistics in paediatric patients versus adults can help to determine whether or not a suspected adverse reaction is likely to be more frequent in paediatric patients.~~

~~Additionally~~, the signalling threshold based on the number of ICSRs received~~,~~ should be adapted to the exposure in the paediatric population as opposed to ~~lower than~~ that for the whole population (for exposure calculation, see GVP Module VII). As the absolute ~~. As the~~ number of cases is usually small, ~~there needs to be a high index of suspicion,~~ comprehensive assessment of ICSRs should be underpinned by ~~individual cases, and~~ a follow-up strategy ~~should be in place to~~ consistently completing~~complete~~ ICSRs with essential information for signal detection and assessment.

Since some adverse reactions might be age-specific, a stratification of the ICSR analysis by age sub-groups can be useful~~essential~~ to yield additional evidence and~~to gain~~ understanding of the risk and/or ~~the~~ risk groups. However, stratification is scientifically justified once an adequate number of cases have been reported and are well documented.

~~[31] Screening for adverse reactions in EudraVigilance; http://www.ema.europa.eu.~~

[32] Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adult suspected adverse drug reactions reported to the European Medicines Agency: implications for pharmacovigilance. Paediatr Drugs. 2014; 16(4): 309-319.

Considering that the nature and/or severity of adverse reactions in paediatric patients may depend on organ maturation stage, any signal detection methods should focus not only on the paediatric population as a whole, but also on specific paediatric subpopulations defined by age or maturation status.

In case of medicinal products with low usage in the paediatric population, early signal detection can prove more challenging. A different, more effective approach to signal detection may be needed, for example using real-worldlife data from patients' records or disease databases and active surveillance systems. Clinical specialist networks and paediatric clinical trial networks may be a useful resource in this context.

P.IV.B.6. Safety communication

For safety communication about paediatric medicines, the general guidance in GVP Module XV on safety communication and GVP Module XVI on risk minimisation measures (RMM) should be followed, together with the additional considerations in this Section.

It should be considered that children and adolescents are nowadays becoming more and moreincreasingly involved in the shared therapeuticmedical decision-making process and, as they are reaching adulthood, they want to engagebe involved in making their own health choices. With the increasing use of the internet, young people also tend to independently seek health information independently. Adolescents . Children above 12 years of age usually take their regularchronic medicine independently, and even younger children may learn to do so. Adolescents usually have a capacitycan and want to understand informationbe informed about medicines in a way similar to that of adults. While they typically also want to be informed comprehensively like adults, the way information is presented to them can be tailored to their interests and preferences as described below., while younger children can be approached with information in an adapted style that takes into account their information needs and capability of processing complex messages and avoidsavoiding a paternalistic style.

Safety communication and communication-based additional RMM should include targeting specific audiences, (e.g. paediatricians, parents/carers or legal representatives, and the paediatric population, as relevant)), and aim at gaining their active participation in risk minimisation and informed therapeutic choice, involving the child as appropriate to their age.

In order to convey information specifically of interest to the paediatric population, marketing authorisation holders and competent authorities are encouraged to address, in the product information and any additional RMM such as educational material, as appropriate, the following if evidence is available and applicable:

- interference of the effects of the medicinal product with school and sports performance;
- interactions with alcohol, nicotine and other pharmacologically active substances;
- risks of diversion of the medicine to friends;.
- advice on the correct administration of the medicine.

Children and adolescentsYounger people have different media preferences from adults and may be more effectively reached by information and educational tools like infographics, comics, video clips and social media channels adapted to their relevant age group. It is encouraged to consider this in the

preparation of additional RMM. Also, additional RMM should be designed with feasibility in mind, e.g. how they can be integrated in the daily life of the young patient and how the acceptability of their use can be optimised. When preparing additional RMM, messages should be tested in conceptual, linguistic and media terms with the paediatric target group reflecting in a proportionate way the seriousness of the risk~~. This should be considered in the preparation of additional RMM~~.

~~In some situations, educational materials for additional RMM targeted to parents/carers should be considered, e.g. when advice on correct administration of a medicine is particularly important or to alert on a risk of diversion and/or misuse.~~

Safety communication and, when necessary, educational materials addressed to healthcare professionals should aid discussion on certain risks with children and their parents/carers or legal representatives. Where applicable, this should include~~the~~ advice addressing~~needs to address~~ common sensitivities and concerns, such as the impact of the medicinal product on growth and development, cognitive and sexual/reproductive functions, and potential long-term effects.

P.IV.C. Operation of the EU network

P.IV.C.1. Roles and responsibilities

P.IV.C.1.1. Marketing authorisation holder and applicant in the EU

The marketing authorisation holder or applicant in the EU has the legal obligation to conduct pharmacovigilance in accordance with the requirements set up in Directive 2001/83/EC and Regulation EC no 726/2004 and should follow~~address~~ the GVP Modules I to XVI, taking into account the considerations specific~~specific aspects relevant~~ to the paediatric population ~~(see P.IV.A.1.)~~ in this P.IV.~~accordance with the guidance provided in 0.~~ The guidance in P.IV.A.~~C.1.~~ should be followed for addressing paediatric-specific aspects when operating pharmacovigilance processes~~in the EU~~.

~~***P.IV.B.6.1.1. Risk management plan (RMP)***~~

~~Further to the guidance in P.IV.B.1., the following should be considered:~~

~~When agreeing a paediatric investigation plan (PIP) (see P.IV.C.2.3.), the Paediatric Committee (PDCO) (see P.IV.C.2.1.) may identify, in the PDCO opinion, potential risks for the paediatric (sub-) population(s), in particular with regard to long-term efficacy and/or safety. PRAC will consider at the moment of the marketing authorisation in a paediatric indication whether the available clinical and non-clinical evidence supports their inclusion as important potential or identified risks, or missing information in the RMP.~~

~~The PDCO might also waive the requirement of paediatric development (Article 11 of the Paediatric Regulation) on the grounds that the specific medicinal product is likely to be ineffective or unsafe of the paediatric population [Article 11(1)(a) of the Paediatric Regulation]. Once the clinical programme has been completed in adults the applicability of such grounds will be confirmed by PRAC and CHMP at the time of MA for potential inclusion of adequate information on paediatric subjects in the summary of product characteristics (SmPC) as well as in the RMP. This aims at setting up appropriate risk minimisation measures should there be a potential paediatric use.~~

~~***P.IV.B.6.1.2. Periodic safety update report (PSUR)***~~

~~Further to the guidance in P.IV.B.3., the following should be considered:~~

Significant findings arising from paediatric clinical trials during the PSUR reporting period should be included in the PSUR, especially when these clinical trials have included safety objectives as part of the agreed PIP opinion which is not yet completed, facilitating cross-linking of information and procedures in the management of the medicinal product life-cycle.

When the PSUR submission is due before the paediatric development is completed, as agreed in a PIP, all information related to the deferred clinical and non-clinical studies should be adequately presented.

Where it is considered beneficial to gather further insight on widened use of a medicine in the paediatric population, this may lead to a requirement for a higher frequency of PSUR submissions as required by means in the List of European Union Reference Dates[33] (see GVP Module VII).

P.IV.B.6.1.3. Post-authorisation safety study (PASS)

Further to the guidance in P.IV.B.4., the following should be considered:

In the case of development of medicines to treat diseases which occur rarely in paediatric patients and for which paediatric data are lacking or very limited, long-term follow-up and maintenance of registries to document the long-term outcome should be considered by the marketing authorisation holder(MAH).

Finally, the clinical study program to be conducted in the paediatric population following initial marketing authorisation (MA) in adults (deferred paediatric clinical studies as described in the PIP opinion) should be reviewed at time of initial marketing authorisation application. This is important because specific safety objectives included in the agreed clinical trial can consequently be considered for inclusion in the RMP (part II, modules SVII and SVIII).

The consultation of specialist networks (e.g. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance [ENCePP][34]) and where appropriate, paediatric clinical trial networks (e.g. Enpr-EMA[35]) could be helpful to address specific aspects related to design and conduct of PASS in paediatrics.

P.IV.C.1.2. European Medicines Agency

For the purpose of safe and effective use of medicinal products in authorised for or used by the paediatric population outside the terms of the marketing authorisation the Pharmacovigilance Risk Assessment Committee (PRAC) (see GVP Module I) and the Paediatric Committee (PDCO) work together.

P.IV.C.1.2.1. The Paediatric Committee (PDCO)

The Paediatric Committee (PDCO) supports the development of such medicines for children in the EUEuropean Union and its principle responsibility, among others, is to assess the content of paediatric investigation plans (PIPs) (see P.IV.C.1.3.)), which determine the studies that must be carried out in the paediatric population when developing a medicine. This includes assessing applications for a full or partial waiver and for a medicinal product. deferrals.

The PDCO composition includes members with expertise in pharmacovigilance to meet the specific challenges of collecting safety data in the paediatric population, including data on possible long-term

[33] www.ema.europa.eu
[34] European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP): http://www.encepp.eu/.
[35] European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA): http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000303.jsp.

effects (see. The Mandate and Rules of Procedure of the PDCO) are published on the Agency's website[36].

PDCO responsibilities also include applications for a full or partial PIP waiver and for study deferrals. Waivers for the requirement of paediatric development are granted by the PDCO - in one or more specific conditions - on different legal grounds. If the specific medicinal product was waived (in accordance to Article 11(1) of the Paediatric Regulation) this aspect will be discussed by the Committee for Medicinal Products for Human Use (CHMP) at the time of assessment of the initial marketing authorisation application, with the aim to include adequate information on paediatric subjects in the summary of product characteristics (SmPC) as well as in the RMP (see P.IV.B.1.), as appropriate.

P.IV.C.1.2.2. Interaction between the PDCO and the Pharmacovigilance Risk Assessment Committee (PRAC)

While the legalregulatory role and competences of the PRAC and the PDCO remain clearly separated, a scientific dialogue and coordination in the respective procedure is anticipatedexpected. The PDCO and the PRAC proactively exchange of information and provide each other reciprocal advice.

The scope of such interaction focuses, for example, on the promotion of early development of risk management strategies, understanding impact of emerging safety issues on paediatric development, gaining insight on paediatric needs and ensuring in general that, when needed, pharmacovigilance activitiesmechanisms are adapted to meet the specific challenges of collecting safety data in the paediatric population.

P.IV.C.1.2. The paediatric investigation plan in the EU (PIP)

A PIP determines theis a development plan aimed at ensuring that the necessary data are obtained through studies that must be carried out in the paediatric population when developing a medicine. This requirement also applies when a marketing , to support the authorisation holder in the EU wants to addof a medicine with a newpaediatric indication, pharmaceutical form or route of administration for a medicine that is already authorised and covered by a supplementary protection certificate (SPC) or a patent that qualifies for the granting of a SPC (Regulation (EC) No 1901/2006).

All applications for marketing authorisation for new medicines in the EU have to include the results of studies as described in the agreed PIP, unless the medicine is exempt because of a waiver or these are not yet available due to a deferral.

Overall a PIP is a research and development programme aimed at ensuring that the necessary data are generated determining the conditions in which a medicinal product may be authorised to treat the paediatric population. A PIP might include for example, interventional and non-interventional studies, non-clinical studies, extrapolation studies, modelling and simulation studies, development of specific paediatric pharmaceutical forms and formulations.

P.IV.C.1.3. The RMP in the EU

All applicationsFurther to the guidance in P.IV.B.1., the following scenarios should be considered:

When agreeing a PIP (see P.IV.C.2.), the PDCO may (in particular with regard to knowledge gaps) identify 'Potential long-term safety/efficacy issues in relation to paediatric use for consideration in the

[20] [36] http://www.ema.europa.eu.

risk management plan/pharmacovigilance activities' (included in addition to the 'Key elements' in section 5 of annex I of the PDCO opinion).

At the time of the evaluation of the submission for initial (or paediatric line extension) marketing authorisation, the applicant in the EU should evaluate whether – based on the available clinical and non-clinical evidence generated after the agreement of the PIP - such previously identified potential issues are still valid, and whether they should be included as important potential or identified risks in the RMP. If no information is available, but there is a potential risk related to off-label use, such potential long-term safety issues might also be considered as missing information in the RMP. The aim would be to set-up appropriate risk minimisation measures, should there be important risks related to off-label used in the paediatric population.

If there are specific safety objectives in the agreed ~~for new medicines in the EU have to include the results of~~ studies of the PIP (e.g. long-term safety studies), of which results can be informative in consideration of any existing safety concern associated with the medicinal product or with any potential for paediatric off-label use, the key findings of these results should be considered for inclusion in part II, modules SVII and SVIII, of the RMP.

Furthermore, if a PIP is still to be conducted in paediatric patients following the initial marketing authorisation in adults (i.e. the paediatric clinical studies listed in the PIP opinion are deferred), it needs to be considered whether studies included in the PIP should also be reflected in the RMP taking into account important risks of~~as described in an agreed PIP, unless~~ the medicine related to potential off-label use in paediatrics.

All these aspects will be assessed by the PRAC and CHMP at the time of marketing authorisation.

P.IV.C.1.4. The PSUR in the EU

Further to the guidance in P.IV.B.3., some other aspects should be considered. Significant findings arising from ongoing and completed paediatric clinical trials during the PSUR reporting interval should be included in the PSUR.~~is exempt because of a deferral or waiver.~~ This is particularly relevant~~requirement also applies~~ when these clinical trials investigate safety objectives that are common to the agreed PIP and particularly when the PSUR submission is due before the paediatric development is completed (see P.IV.C.2.). This aims at facilitating cross-linking of information and procedures in the management of the medicinal product life-cycle.

When it is considered beneficial to gather further insight on widened use of a medicine in the paediatric population, a higher frequency of PSUR submissions as required by means in the List of European Union Reference Dates[37] might be needed (see GVP Module VII).

P.IV.C.1.5. Designing PASS

Further to the guidance in P.IV.B.4., the following aspects should be considered:

The template for PASS protocols should be completed in accordance with guidance provided in GVP Module VIII and Guidance for the Format and Content of the Protocol of Non-Interventional Post-Authorisation Safety Studies[38], taking into account specifics for paediatrics as follows:

- template heading 8 "Research question and objectives": this may relate to alterations in physical growth, puberty, cognitive or physical development;

[37] www.ema.europa.eu.
[38] www.ema.europa.eu.

- template heading 9.4 “Data sources”: if information from other family members or from external data sources, such as census data, is needed, the linkages to external data sources should be described (e.g. exposures and events in neonates are often included in the mother’s clinical record rather than in a separate record for the child);

- template heading 9.7 “Data analysis”: the statistical methods may need to be adapted to account for paediatric-specific aspects (e.g. the correlation between repeated measurements such as weight and height in the same child which may vary in short periods of time, changes in recommended dosing as the child grows, use of age-appropriate normalised laboratory values, metabolism specificities due to maturation).

In the case of a development of a medicine to treat rare diseases in paediatric patients for which paediatric data are lacking, or very limited, registries or other means of long-term data collection could be considered by the marketing ~~a marketing~~ authorisation holder to enable the conduction of appropriate PASS to follow-up and appropriately document long-term safety.

In these cases, high level planning of paediatric registries and related PASS should ~~wants to add a new indication, pharmaceutical form or route of administration for a medicine that is~~ already be considered at the time of submission of a PIP (see P.IV.C.2.), to promote continuity in the generation of safety data between the pre- and post-authorisation phase (as already highlighted in P.IV.B.4.) ~~authorised and covered by intellectual property rights.~~

~~P.IV.C.2. Safety~~ The consultation of specialist networks (e.g. the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)[39]) and, where appropriate, the paediatric clinical trial networks (e.g. the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)[40]) could be helpful to address specific aspects related to design and conduct of PASS in paediatrics. The applicants/marketing authorisation holder in the EU is also encouraged to request scientific advice (SA) from the Agency on specific aspects of PASS protocols, especially for complex or controversial issues or for innovative approaches or methodologies including those for paediatric studies[41].

P.IV.C.1.6. Signal management within the EU regulatory network

In addition to the guidance in P.IV.B.5., ICSRs for paediatric patients should be analysed by means of tools provided by EudraVigilance separately from ICSRs for adult patients (e.g. electronic Reaction Monitoring Reports (eRMRs)[42]).

It is recommended that statistics of disproportionate reporting (see GVP Module IX Addendum I) are calculated using only ICSRs about paediatric patients to increase the ability to detect paediatric signals of disproportionate reporting (SDR) from appropriate databases, i.e. EudraVigilance in the EU. Sub-group analysis by age and comparison of the disproportionality statistics in paediatric patients versus adults (if applicable, depending on the size of the data set) can help to determine whether or not a suspected adverse reaction is likely to be more frequent in paediatric patients.

P.IV.C.1.7. Safety communication in the EU

Further to the guidance in P.IV.B.5~~P.IV.B.5~~., children and their families in the EU can be consulted by the marketing authorisation holder in the EU as well as by the Agency and competent authorities in

[39] European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), www.encepp.eu/.
[40] European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), www.ema.europa.eu.
[41] Scientific advice and protocol assistance; www.ema.europa.eu.
[42] Screening for adverse reactions in EudraVigilance; www.ema.europa.eu.

Member States~~,~~ through the established Young Person Advisory Groups ~~(YPAG) can be consulted~~ for the preparation and revision of safety communication and educational materials for additional RMMs (see Principles on the Involvement of Young Patients and Consumers Within EMA Activities[43]). The Enpr-EMA~~. To this extent it is important to emphasise the activities of the EnprEMA~~ Working Group on Young Persons Advisory Groups (YPAGs)~~which is~~ currently works~~working~~ on resources and on establishing a framework of interaction, which will become available for the Agency and the EU regulatory network as well as ~~for the EMA and~~ marketing authorisation holders in the EU.

[43] www.ema.europa.eu.